Andrographolide And Its Analogues in Colon Cancer (Anti-tumor Activity)

Main Article Content

Radharaman Tiwari
Harsha Rathore
Ravindra Mishra
Vinay Jain


The large intestine (colon), where colorectal cancer, also known as colon cancer, first appears, is a cancer that greatly affects death rates across the world. Although the present methods of treating colon cancer largely aim to reduce symptoms, neither a cure nor a reversal of the disease's course are offered. Finding novel therapeutics that are efficient, conclusive, and toxic-free is therefore urgently needed. Examining phytochemical, which have drawn interest as substitute and superior remedies for treating a variety of illnesses, is one intriguing strategy. Plants are abound in phytochemical, which are secondary compounds with biological activity but no nutritional value. Among these substances, Andrographolide and its derivatives derived from the  medicinal plant Andrographis paniculata have been widely employed in different  traditional medicinal systems for treating various diseases, including cardiovascular conditions.
In this review, we look into the in-vivo and in-vitro anticancer activity of Andrographolide and its  derivatives. Through tailored drug development techniques that not only concentrate on conventional routes but also incorporate particular signaling pathways, Andrographolide's demonstrate their anticancer benefits.

Along with the suppression of the P13K/Akt pathway, which is linked to inflammation and  activation the Nrf-2/HO-1 system, which is linked to antioxidant processes, these pathways include Wnt/-catenin, Hippo, Hedgehog,NF-B, STAT, p53 and P13-K/AKT/ERK. Through anti-arrhythmic, anti-hypertensive, anti-inflammatory and antioxidant mechanisms, animal studies have demonstrated that Andrographolide and its derivatives are effective against cancer. As a result, Andrographolide and its derivatives may prove to be excellent candidates for the creation of brand-new colorectal cancer treatment compounds. In the near future, more investigation and study in this area might result in viable therapy possibilities.

Article Details

How to Cite
Radharaman Tiwari, Harsha Rathore, Ravindra Mishra, & Vinay Jain. (2023). Andrographolide And Its Analogues in Colon Cancer (Anti-tumor Activity). Journal of Coastal Life Medicine, 11(2), 616–631. Retrieved from


American College of Gastroenterology Chronic Constipation Task Force. "An evidence-based approach to the management of chronic constipation in North America." Official journal of the American College of Gastroenterology| ACG 100 (2005): S1-S4.

Jasperson, K. W., Tuohy, T. M., Neklason, D. W. & Burt, R. W. Hereditary and familial colon cancer. Gastroenterology 138, 2044–2058 (2010).

American Cancer Society. Atlanta, Georgia: American Cancer Society; 2021. Accessed January 22, 2021. [Google Scholar]

Fukuda I, Hizuka N, Murakami Y, et al. Clinical features and therapeutic outcomes of 65 patients with acromegaly at Tokyo Women’s Medical University. Intern Med. 2001;40(10):987-992. doi: 10.2169/internalmedicine.40.987. [PubMed] [CrossRef] [Google Scholar]

Kelly SR and Nelson H. Chapter 75 – Cancer of the Rectum. In: Niederhuber JE, Armitage JO, Dorshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 6th ed.Philadelphia, Pa. Elsevier: 2020.

Lawler M, Johnston B, Van Schaeybroeck S, Salto-Tellez M, Wilson R, Dunlop M, and Johnston PG. Chapter 74 – Colorectal Cancer. In: Niederhuber JE, Armitage JO, Dorshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 6th ed. Philadelphia, Pa. Elsevier: 2020.

Libutti SK, Saltz LB, Willett CG, and Levine RA. Ch 62 - Cancer of the Colon, Ch 63 - Cancer of the Rectum. In: DeVita VT, Hellman S, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 11th ed. Philadelphia, Pa: Lippincott-Williams & Wilkins; 2019.

National Cancer Institute. Physician Data Query (PDQ). ColonRectal Cancer Treatment. 2020. Accessed at on February 19, 2020.

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. V.1.2020. Accessed at on Feb 19, 2020, on Feb 19, 2020.

Riley JM, Cross AW, Paulos CM, et al. The clinical implications of immunogenomics in colorectal cancer: A path for precision medicine. Cancer. 2018 Jan 9.

Wright M, Beaty JS, Ternent CA. Molecular Markers for Colorectal Cancer. Surg Clin North Am. 2017;97(3):683-701.

S. K. Mishra, N. S. Sangwan and R. S. Sangwan: Andrographis paniculata (Kalmegh): a review. Pharmacog Rev, 1(2), 283 (2007)

S. K. Mishra and M. K. Kim: Vitamin A and Cancer Risk. In: Vitamin A and Carotenoids. Ed V. R. Preedy. Royal Society of Chemistry, London (2012)DOI: 10.1039/9781849735506-00485

C. Wiart, K. Kumar, M. Yusof, H. Hamimah, Z. Fauzi and M. Sulaiman: Antiviral properties of ent-labdene diterpenes of Andrographis paniculatanees, inhibitors of herpes simplex virus type 1. Phytother Res, 19(12), 1069-1070 (2005)DOI: 10.1002/ptr.1765

S. Rajagopal, R. A. Kumar, D. S. Deevi, C. Satyanarayana and R. Rajagopalan: Andrographolide, a potential cancer therapeutic agent isolated from Andrographis paniculata. J Exp TherOncol, 3(3), 147-58 (2003) DOI: 10.1046/j.1359-4117.2003.01090.x

W. Deng, R. Nie and J. Liu: Comparison of pharmacological effect of four Andrographolides. Chinese Pharma Bull, 17, 195-198 (1982)

B. Shukla, P. K. Visen, G. K. Patnaik and B. N. Dhawan: Choleretic effect of Andrographolide in rats and guinea pigs. Planta Med, 58(2), 146-9 (1992) DOI: 10.1055/s-2006-961416

A. Puri, R. Saxena, R. P. Saxena, K. C. Saxena, V. Srivastava and J. S. Tandon: Immunostimulant agents from Andrographis paniculata. J Nat Prod, 56(7), 995-9 (1993) DOI: 10.1021/np50097a002.

Valdiani, M. A. Kadir, S. G. Tan, D. Talei, M. P. Abdullah and S. Nikzad: Nain-e Havandi Andrographis paniculata present yesterday, absent today: a plenary review on underutilized herb of Iran’s pharmaceutical plants. Mol Biol Rep, 39(5), 5409-24 (2012) DOI: 10.1007/s11033-011-1341-x

J. C. Lim, T. K. Chan, D. S. Ng, S. R. Sagineedu, J. Stanslas and W. S. Wong: Andrographolide and its analogues: versatile bioactive molecules for combating inflammation and cancer. Clin Exp PharmacolPhysiol, 39(3), 300-10 (2012) DOI: 10.1111/j.1440-1681.2011.05633.x

A. Sharma, K. Lal and S. S. Handa: Standardization of the indian crude drug kalmegh by high pressure liquid chromatographic determination of Andrographolide. Phytochem Anal, 3(3), 129-131 (1992) DOI: 10.1002/pca.2800030308

T. Matsuda, M. Kuroyanagi, S. Sugiyama, K. Umehara, A. Ueno and K. Nishi: Cell differentiation-inducing diterpenes from Andrographis paniculataNees. Chem Pharma Bull, 42(6), 1216-25 (1994) DOI: 10.1248/cpb.42.1216

V. K. Dua, V. P. Ojha, R. Roy, B. C. Joshi, N. Valecha, C. U. Devi, M. C. Bhatnagar, V. P. Sharma and S. K. Subbarao: Antimalarial activity of some xanthones isolated from the roots of Andrographis paniculata. J Ethnopharmacol, 95(2-3), 247-51 (2004) DOI: 10.1016/j.jep.2004.07.008

U. Sirion, S. Kasemsook, K. Suksen, P. Piyachaturawat, A. Suksamrarn and R. Saeeng: New substituted C-19Andrographolide analogues with potent cytotoxic activities. Bioorg Med Chem Lett, 22(1), 49-52 (2012) DOI: 10.1016/j.bmcl.2011.11.085

M. L. Tan, H. K. Tan, C. E. Oon, M. Kuroyanagi and T. S. Muhammad: Identification of genes involved in the regulation of 14-deoxy-11,12didehydroAndrographolide-induced toxicity in T-47D mammary cells. Food Chem Toxicol, 50(2), 431-44 (2012) DOI: 10.1016/j.fct.2011.11.001

A. D. Thingale, K. S. Shaikh, P. R. Channekar, U. C. Galgatte, P. D. Chaudhari and C. Bothiraja: Enhanced hepatoprotective activity of Andrographolide complexed with a biomaterial. Drug Deliv, (2014) DOI: 10.3109/10717544.2013.871602

S. S. Handa and A. Sharma: Hepatoprotective activity of Andrographolide from Andrographis paniculata against carbontetrachloride. Ind J Med Res, 92, 276-83 (1990)

C. Tang, G. Gu, B. Wang, X. Deng, X. Zhu, H. Qian and W. Huang: Design, synthesis, and biological evaluation of Andrographolide derivatives as potent hepatoprotective agents. Chem Biol Drug Des, 83(3), 324-33 (2014) DOI: 10.1111/cbdd.12246

N. P. Trivedi, U. M. Rawal and B. P. PaTel: Potency of Andrographolide as an antitumor compound in BHC-induced liver damage. Integr Cancer Ther, 8(2), 177-89 (2009) DOI: 10.1177/1534735409335606

P. K. Visen, B. Saraswat, V. Vuksan and B. Dhawan: Effect of Andrographolide on monkey hepatocytes against galactosamine induced cell toxicity: an in-vitro study. J Comp Integr Med, 4(1) (2007)

P. K. Visen, B. Shukla, G. K. Patnaik and B. N. Dhawan: Andrographolide protects rat hepatocytes against paracetamolinduced damage. J Ethnopharmacol, 40(2), 131-6 (1993) DOI: 10.1016/0378-8741(93)90058-D

Y. F. Xia, B. Q. Ye, Y. D. Li, J. G. Wang, X. J. He, X. Lin, X. Yao, D. Ma, A. Slungaard, R. P. Hebbel, N. S. Key and J. G. Geng: Andrographolide attenuates inflammation by inhibition of NF-kappa B activation through covalent modification of reduced cysteine 62 of p50. J Immunol, 173(6), 4207-17 (2004) DOI: 10.4049/jimmunol.173.6.4207

Y. J. Wang, J. T. Wang, Q. X. Fan and J. G. Geng: Andrographolide inhibits NF-kappaBeta activation and attenuates neointimal hyperplasia in arterial restenosis. Cell Res, 17(11), 933-41 (2007) DOI: 10.1038/cr.2007.89

N. Mackman: Regulation of the tissue factor gene. ThrombsHaemo, 78(1), 747-54 (1997)

Y. D. Li, B. Q. Ye, S. X. Zheng, J. T. Wang, J. G. Wang, M. Chen, J. G. Liu, X. H. Pei, L. J. Wang, Z. X. Lin, K. Gupta, N. Mackman, A. Slungaard, N. S. Key and J. G. Geng: NF-kappaB transcription factor p50 critically regulates tissue factor in deep vein thrombosis. J Biol Chem, 284(7), 4473-83 (2009) DOI: 10.1074/jbc.M806010200

L. Huang: The effects of Andrographolides on experimental blood deficiency of cardiac muscle. Chin Herb Med, 18(7), 26-28 (1987)

H. W. Chen, A. H. Lin, H. C. Chu, C. C. Li, C. W. Tsai, C. Y. Chao, C. J. Wang, C. K. Lii and K. L. Liu: Inhibition of TNF-alphaInduced Inflammation by Andrographolide via down-regulation of the PI3K/Akt signaling pathway. J Nat Prod, 74(11), 2408-13 (2011) DOI: 10.1021/np200631v

H. R. Tsai, L. M. Yang, W. J. Tsai and W. F. Chiou: Andrographolide acts through inhibition of ERK1/2 and Akt phosphorylation to suppress chemotactic migration. Eur J Pharmacol, 498(1-3), 45-52 (2004) DOI: 10.1016/j.ejphar.2004.07.077

L. J. Wang, X. Zhou, W. Wang, F. Tang, C. L. Qi, X. Yang, S. Wu, Y. Q. Lin, J. T. Wang and J. G. Geng: Andrographolide inhibits oral squamous cell carcinogenesis through NF-kappaB inactivation. J Dent Res, 90(10), 1246-52 (2011) DOI: 10.1177/0022034511418341

K. C. Lee, H. H. Chang, Y. H. Chung and T. Y. Lee: Andrographolide acts as an antiinflammatory agent in LPS-stimulated RAW264.7. macrophages by inhibiting STAT3-mediated suppression of the NF-kappaB pathway. J Ethnopharmacol, 135(3), 678-84 (2011) DOI: 10.1016/j.jep.2011.03.068

V. Chandrasekaran, P. Thiyagarajan, H. B. Deepak and A. Agarwal: In vitro modulation of LPS/calcimycin induced inflammatory and allergic mediators by pure compounds of Andrographis paniculata (King of bitters) extract. IntImmunopharmacol, 11(1), 79-84 (2011) DOI: 10.1016/j.intimp.2010.10.009

Y. Chao, C. K. Lii, I. T. Tsai, C. C. Li, K. L. Liu, C. W. Tsai and H. W. Chen: Andrographolide inhibits ICAM-1 expression and NF-kappaB activation in TNF-alpha-treated EA.hy926 cells. J Agric Food Chem, 59(10), 5263-71 (2011) DOI: 10.1021/jf104003y

W. Chen, L. Feng, H. Nie and X. Zheng: Andrographolide induces autophagic cell death in human liver cancer cells through cyclophilin D-mediated mitochondrial permeability transition pore. Carcinogenesis, 33(11), 2190-8 (2012) DOI: 10.1093/carcin/bgs264

Y. C. Shen, C. F. Chen and W. F. Chiou: Andrographolide prevents oxygen radical production by human neutrophils: possible mechanism(s) involved in its anti-inflammatory effect. Br J Pharmacol, 135(2), 399-406 (2002) DOI: 10.1038/sj.bjp.0704493

W. F. Chiou, C. F. Chen and J. J. Lin: Mechanisms of suppression of inducible nitric oxide synthase (iNOS) expression in RAW 264.7. cells by Andrographolide. Br J Pharmacol, 129(8), 1553-60 (2000) DOI: 10.1038/sj.bjp.0703191

L. Ying and L. J. Hofseth: An emerging role for endothelial nitric oxide synthase in chronic inflammation and cancer. CanRes, 67(4), 1407-10 (2007) DOI: 10.1158/0008-5472.CAN-06-2149

Hanahan and R. A. Weinberg: Hallmarks of cancer: the next generation. Cell, 144(5), 646-74 (2011) DOI: 10.1016/j.cell.2011.02.013

D. J. Newman and G. M. Cragg: Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod, 75(3), 311-35 (2012) DOI: 10.1021/np200906s

B. B. Zhou, H. Zhang, M. Damelin, K. G. Geles, J. C. Grindley and P. B. Dirks: Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov, 8(10), 806-23 (2009) DOI: 10.1038/nrd2137

Y. A. Kim, M. Y. Kim, H. Y. Yu, S. K. Mishra, J. H. Lee, K. S. Choi, J. H. Kim, Y. K. Xiang and Y. S. Jung: Gadd45beta is transcriptionally activated by p53 via p38alpha-mediated phosphorylation during myocardial ischemic injury. J Mol Med (Berl), 91(11), 1303-13 (2013) DOI: 10.1007/s00109-013-1070-9

S. K. Mishra, J. H. Kang, D. K. Kim, S. H. Oh and M. K. Kim: Orally administered aqueous extract of Inonotus obliquus ameliorates acute inflammation in dextran sulfate sodium (DSS)-induced colitis in mice. J Ethnopharmacol, 143(2), 524-32 (2012) DOI: 10.1016/j.jep.2012.07.008

S. K. Mishra, J. H. Kang, C. W. Lee, S. H. Oh, J. S. Ryu, Y. S. Bae and H. M. Kim: Midazolam induces cellular apoptosis in human cancer cells and inhibits tumor growth in xenograft mice. Mol Cells, 36(3), 219-26 (2013) DOI: 10.1007/s10059-013-0050-9

S. K. Mishra, J.-H. Kang, K.-H. Song, M. S. Park, D.-K. Kim, Y.-J. Park, C. Choi, H. M. Kim, M. K. Kim and S. H. Oh: Inonotus obliquus suppresses proliferation of colorectal cancer cells and tumor growth in mice models by downregulation of β-catenin/NF-κB-signaling pathways. Eur J Inflamm, 11(3), 615-629 (2013)

R. A. Kumar, K. Sridevi, N. V. Kumar, S. Nanduri and S. Rajagopal: Anticancer and immunostimulatory compounds from Andrographis paniculata. J Ethnopharmacol, 92(2-3), 291-5 (2004) DOI: 10.1016/j.jep.2004.03.004

S. Nanduri, V. K. Nyavanandi, S. S. Thunuguntla, S. Kasu, M. K. Pallerla, P. S. Ram, S. Rajagopal, R. A. Kumar, R. Ramanujam, J. M. Babu, K. Vyas, A. S. Devi, G. O. Reddy and V. Akella: Synthesis and structure-activity relationships of Andrographolide analogues as novel cytotoxic agents. Bioorg Med Chem Lett, 14(18), 4711-7 (2004) DOI: 10.1016/j.bmcl.2004.06.090

H. P. Chao, C. D. Kuo, J. H. Chiu and S. L. Fu: Andrographolide exhibits anti-invasive activity against colon cancer cells via inhibition of MMP2 activity. Planta Med, 76(16), 1827-33 (2010) DOI: 10.1055/s-0030-1250039

Y. H. Lai, S. L. Yu, H. Y. Chen, C. C. Wang, H. W. Chen and J. J. Chen: The HLJ1-targeting drug screening identified Chinese herb Andrographolide that can suppress tumourgrowth and invasion in non-small-cell lung cancer. Carcinogenesis, 34(5), 1069-80 (2013) DOI: 10.1093/carcin/bgt005

P. Pratheeshkumar and G. Kuttan: Andrographolide inhibits human umbilical vein endothelial cell invasion and migration by regulating MMP-2 and MMP-9 during angiogenesis. J Environ PatholToxicol Oncol, 30(1), 33-41 (2011) DOI: 10.1615/JEnvironPatholToxicolOncol.v30.i1.40

S. H. Liu, C. H. Lin, F. P. Liang, P. F. Chen, C. D. Kuo, M. M. Alam, B. Maiti, S. K. Hung, C. W. Chi, C. M. Sun and S. L. Fu: Andrographolide downregulates the v-Src and Bcr-Abl oncoproteins and induces Hsp90 cleavage in the ROS-dependent suppression of cancer malignancy. BiochemPharmacol, 87(2), 229-42 (2014) DOI: 10.1016/j.bcp.2013.10.014

A. Jaruchotikamol, K. Jarukamjorn, W. Sirisangtrakul, T. Sakuma, Y. Kawasaki and N. Nemoto: Strong synergistic induction of CYP1A1 expression by Andrographolide plus typical CYP1A inducers in mouse hepatocytes. Toxicol App Pharmacol, 224(2), 156-62 (2007) DOI: 10.1016/j.taap.2007.07.008

J. Li, H. Y. Cheung, Z. Zhang, G. K. Chan and W. F. Fong: Andrographolide induces cell cycle arrest at G2/M phase and cell death in HepG2 cells via alteration of reactive oxygen species. Eur J Pharmacol, 568(1-3), 31-44 (2007) DOI: 10.1016/j.ejphar.2007.04.027

K. K. Shen, T. Y. Liu, C. Xu, L. L. Ji and Z. T. Wang: Andrographolide inhibits hepatoma cells growth and affects the expression of cell cycle related proteins. Acta Pharma Sinica, 44(9), 973-9 (2009)

J. Zhou, S. E. Hu, S. H. Tan, R. Cao, Y. Chen, D. Xia, X. Zhu, X. F. Yang, C. N. Ong and H. M. Shen: Andrographolide sensitizes cisplatin-induced apoptosis via suppression of autophagosomelysosome fusion in human cancer cells. Autophagy, 8(3), 338-49 (2012) DOI: 10.4161/auto.18721

Y. Y. Zhu, G. Yu, Y. Zhang, Z. Xu, Y. Q. Wang, G. R. Yan and Q. Y. He: A novel Andrographolide derivative AL-1 exerts its cytotoxicity on K562 cells through a ROSdependent mechanism. Proteomics, 13(1), 169-78 (2013) DOI: 10.1002/pmic.201200273

Y. Li, P. Zhang, F. Qiu, L. Chen, C. Miao, J. Li, W. Xiao and E. Ma: Inactivation of PI3K/Akt signaling mediates proliferation inhibition and G2/M phase arrest induced by Andrographolide in human glioblastoma cells. Life Sci, 90(25-26), 962-7 (2012) DOI: 10.1016/j.lfs.2012.04.044

T. Suriyo, N. Pholphana, N. Rangkadilok, A. Thiantanawat, P. Watcharasit and J. Satayavivad: Andrographis paniculata Extracts and Major Constituent

Diterpenoids Inhibit Growth of Intrahepatic Cholangiocarcinoma Cells by Inducing Cell Cycle Arrest and Apoptosis. Planta Med, 80(7), 533-543 (2014) DOI: 10.1055/s-0034-1368399

D. Chen, Y. Song, Y. Lu and X. Xue: Synthesis and in vitro cytotoxicity of Andrographolide-19-oic acid analogues as anti-cancer agents. Bioorg Med Chem Lett, 23(11), 3166-9 (2013) DOI: 10.1016/j.bmcl.2013.04.010

S. H. Kaufmann and W. C. Earnshaw: Induction of apoptosis by cancer chemotherapy. Exp Cell Res, 256(1), 42-9 (2000) DOI: 10.1006/excr.2000.4838S. Sukumari-Ramesh, J. N. Bentley, M.

D. Laird, N. Singh, J. R. Vender and K. M. Dhandapani: Dietary phytochemicals induce p53- and caspase-independent cell death in human neuroblastoma cells. Int J Dev Neurosci, 29(7), 701-10 (2011) DOI: 10.1016/j.ijdevneu.2011.06.002

Y. Wu and B. P. Zhou: Inflammation: a driving force speeds cancer metastasis. Cell Cycle, 8(20), 3267-73 (2009) DOI: 10.4161/cc.8.20.9699

L. Yang, D. Wu, K. Luo, S. Wu and P. Wu: Andrographolide enhances 5-fluorouracil-induced apoptosis via caspase-8-dependent mitochondrial pathway involving p53 participation in hepatocellular carcinoma (SMMC-7721) cells. Can Lett, 276(2), 180-188 (2009) DOI: 10.1016/j.canlet.2008.11.015

J. Zhou, G. D. Lu, C. S. Ong, C. N. Ong and H. M. Shen: Andrographolide sensitizes cancer cells to TRAIL-induced apoptosis via p53-mediated death receptor 4 up-regulation. Mol Can Ther, 7(7), 2170-80 (2008) DOI: 10.1158/1535-7163.MCT-08-0071

Y. Tan, K. H. Chiow, D. Huang and S. H. Wong: Andrographolide regulates epidermal growth factor receptor and transferrin receptor trafficking in epidermoid carcinoma (A-431) cells. Br J Pharmacol, 159(7), 1497-510 (2010) DOI: 10.1111/j.1476-5381.2009.00627.x

J. Y. Chun, R. Tummala, N. Nadiminty, W. Lou, C. Liu, J. Yang, C. P. Evans, Q. Zhou and A. C. Gao: Andrographolide, an herbal medicine, inhibits interleukin-6 expression and suppresses prostate cancer cell growth. Genes Can, 1(8), 86876 (2010) DOI: 10.1177/1947601910383416

J. Nateewattana, R. Saeeng, S. Kasemsook, K. Suksen, S. Dutta, S. Jariyawat, A. Chairoungdua, A. Suksamrarn and P. Piyachaturawat: Inhibition of topoisomerase II alpha activity and induction of apoptosis in mammalian cells by semi-synthetic Andrographolide analogues. Invest New Drugs, 31(2), 32032 (2013) DOI: 10.1007/s10637-012-9868-9

S. Kumar, H. S. Patil, P. Sharma, D. Kumar, S. Dasari, V. G. Puranik, H. V. Thulasiram and G. C. Kundu: Andrographolide inhibits osteopontin expression and breast tumor growth through down regulation of PI3 kinase/Akt signaling pathway. Curr Mol Med, 12(8), 952-66 (2012) DOI: 10.2174/156652412802480826

M. D. Shi, H. H. Lin, Y. C. Lee, J. K. Chao, R. A. Lin and J. H. Chen: Inhibition of cellcycle progression in human colorectal carcinoma Lovo cells by Andrographolide. Chem-Bio Inter, 174(3), 201-10 (2008) DOI: 10.1016/j.cbi.2008.06.006

J. Nateewattana, S. Dutta, S. Reabroi, R. Saeeng, S. Kasemsook, A. Chairoungdua, J. Weerachayaphorn, S. Wongkhamand P. Piyachaturawat: Induction of apoptosis in cholangiocarcinoma by an Andrographolide analogue is mediated through topoisomerase II alpha inhibition. Eur J Pharmacol, 723, 148-55 (2014) DOI: 10.1016/j.ejphar.2013.12.002

P. Roy, S. Das, A. Mondal, U. Chatterji and A. Mukherjee: Nanoparticle engineering enhances anticancer efficacy of Andrographolide in MCF-7 cells and mice bearing EAC. Curr Pharma Biotech, 13(15), 2669-81 (2012) DOI: 10.2174/138920112804724855

H. H. Lin, C. W. Tsai, F. P. Chou, C. J. Wang, S. W. Hsuan, C. K. Wang and J. H. Chen: Andrographolide down-regulates hypoxia-inducible factor-1alpha in human non-small cell lung cancer A549 cells. Toxicol Appl Pharmacol, 250(3), 336-45 (2011) DOI: 10.1016/j.taap.2010.11.014

K. Sheeja and G. Kuttan: Protective effect of Andrographis paniculata and Andrographolide on cyclophosphamideinduced urothelial toxicity. Integr Can Ther, 5(3), 244-51 (2006) DOI: 10.1177/1534735406291984

H. J. Hocker, K. J. Cho, C. Y. Chen, N. Rambahal, S. R. Sagineedu, K. Shaari, J. Stanslas, J. F. Hancock and A. A. Gorfe: Andrographolide derivatives inhibit guanine nucleotide exchange and abrogate oncogenic Ras function. Proc Natl Acad Sci U S A, 110(25), 10201-6 (2013) DOI: 10.1073/pnas.1300016110

S. Kasemsuk, U. Sirion, K. Suksen, P. Piyachaturawat, A. Suksamrarn and R. Saeeng: 12-Amino-Andrographolide analogues: synthesis and cytotoxic activity. ArchPharmaRes, 36(12), 145464 (2013) DOI: 10.1007/s12272-013-0152-0